For research and educational purposes only. Not medical advice.

Survodutide Reference

Educational, not medical advice reference for Survodutide: GLP-1, Fat Loss; regulatory status, evidence posture, source review, and schedule not…

Reference summary

Phase 2 MASH/MASH-fibrosis trial (Sanyal 2024 NEJM, n=293 adults with biopsy-confirmed MASH, 48 weeks) reported MASH improvement in 47 to 62 percent of survodutide groups (for example 62 percent at the 4.8 mg dose and 43 percent at 6.0 mg) versus 14 percent on placebo, with concurrent reduction in liver fat and improvement in fibrosis biomarkers. The Phase 3 SYNCHRONIZE-1 obesity trial reported positive sponsor topline on April 28, 2026 (up to 16.6 percent mean weight loss at 76 weeks versus 3.2 percent on placebo); the LIVERAGE and LIVERAGE-Cirrhosis Phase 3 MASH trials are ongoing with readouts expected later in 2026. Common adverse events were dose-dependent gastrointestinal (nausea, vomiting, diarrhea).

Regulatory and posture

Categories
GLP-1, Fat Loss
Aliases
BI 456906, GLP-1 / glucagon dual receptor agonist
Evidence posture
human - Phase 2 MASH data are published and the Phase 3 SYNCHRONIZE-1 obesity trial reported positive topline in April 2026; the Phase 3 MASH program is ongoing. Survodutide remains investigational.
Regulatory status
Investigational. Survodutide is a GLP-1 / glucagon dual receptor agonist developed by Boehringer Ingelheim and Zealand Pharma; the Phase 3 SYNCHRONIZE program covers obesity and the LIVERAGE program covers MASH / MASH-fibrosis. The Phase 3 SYNCHRONIZE-1 obesity trial reported positive topline in April 2026. There is no FDA-approved drug label, and survodutide is not on FDA's approved bulk-substances list for compounding.
Content review status
investigational verified

Selected public sources

Related tools